Similar articles

Abstract: Objective: hepatocellular carcinoma (HCC) is still one of the most common death-related malignancies worldwide. Because the way onset and progression are hidden most, HCC diagnoses are made at an advanced stage, when they are unsuitable for surgical resection. microRNAs are a class of small non-coding RNAs, participating in many aspects of cancers. In this study, we tried to establish the role of microRNA-718 (miR-718) in the malignant phenotype of HCC cells and its possible role in HCC diagnosis. Methods: Here we first used a methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay, Transwell migration and invasion assays, and colony formation assay to evaluate the impact of miR-718 on the malignant phenotypes of HCC cells. Then, we used bioinformatic methods to predict the target gene of miR-718 and used green fluorescence protein (GFP) reporter assay, Western blot, and quantitative real-time polymerase chain reaction (qRT-PCR) to validate the regulation relationship. Finally, we determined the role of the target gene in the HCC phenotype. Results: We found that the expression of miR-718 was significantly reduced in various HCC cell lines and HCC tissues. Re-expression of miR-718 significantly reduced the cellular viability and colony formation ability as well as inhibited the migration and invasion abilities of HCC cell lines. early growth response protein 3 (EGR3) is a direct target of miR-718 and is negatively regulated by miR-718. EGR3 could increase the viability and proliferation of HCC cells, and promot the migration and invasion of HCC cells. Conclusions: miR-718 acts as a tumor suppressive microRNA in HCC via regulating the expression of EGR3, which may provide a new diagnostic marker and treatment target for HCC.

miR-718和EGR3参与调控肝癌细胞系的恶性表型的研究

[1]Ameres, S.L., Zamore, P.D., 2013. Diversifying microRNA sequence and function. Nat. Rev. Mol. Cell Biol., 14(8):475-488.

[2]Baron, V.T., Pio, R., Jia, Z., et al., 2015. Early growth response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer. Br. J. Cancer, 112(4):755-764.

[3]Bartel, D.P., 2009. MicroRNAs: target recognition and regulatory functions. Cell, 136(2):215-233.

[4]Bronte, F., Bronte, G., Fanale, D., et al., 2015. Hepatomirnoma: the proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma. Crit. Rev. Oncol. Hematol., 97:312-321.

[5]Fang, F., Shangguan, A.J., Kelly, K., et al., 2013. Early growth response 3 (Egr-3) is induced by transforming growth factor-β and regulates fibrogenic responses. Am. J. Pathol., 183(4):1197-1208.

[6]Farazi, T.A., Juranek, S.A., Tuschl, T., 2008. The growing catalog of small RNAs and their association with distinct Argonaute/Piwi family members. Development, 135(7):1201-1214.

[7]Felekkis, K., Touvana, E., Stefanou, C., et al., 2010. MicroRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia, 14(4):236-240.

[8]Fong, Z.V., Tanabe, K.K., 2014. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. Cancer, 120(18):2824-2838.

[9]Gomez-Martin, D., Diaz-Zamudio, M., Galindo-Campos, M., et al., 2010. Early growth response transcription factors and the modulation of immune response: implications towards autoimmunity. Autoimmun. Rev., 9(6):454-458.

[10]Hu, X., Schwarz, J.K., Lewis, J.S., et al., 2010. A microRNA expression signature for cervical cancer prognosis, Cancer Res., 70(4):1441-1448.

[11]Kimhofer, T., Fye, H., Taylor-Robinson, S., et al., 2015. Proteomic and metabonomic biomarkers for hepatocellular carcinoma: a comprehensive review. Br. J. Cancer, 112(7):1141-1156.

[12]Leng, R., Zha, L., Tang, L., 2014. MiR-718 represses VEGF and inhibits ovarian cancer cell progression. FEBS Lett., 588(12):2078-2086.

[13]Li, L., Yun, S.H., Keblesh, J., et al., 2007. Egr3, a synaptic activity regulated transcription factor that is essential for learning and memory. Mol. Cell. Neurosci., 35(1):76-88.

[14]Liao, F., Ji, M.Y., Shen, L., et al., 2013. Decreased Egr3 expression is related to poor prognosis in patients with gastric cancer. J. Mol. Histol., 44(4):463-468.

[15]Lin, M., Chen, W., Huang, J., et al., 2011. MicroRNA expression profiles in human colorectal cancers with liver metastases. Oncol. Rep., 25(3):739-747.

[16]Perez-Cadahia, B., Drobic, B., Davie, J.R., 2011. Activation and function of immediate-early genes in the nervous system. Biochem. Cell Biol., 89(1):61-73.

[17]Pio, R., Jia, Z., Baron, V.T., et al., 2013. Early growth response 3 (Egr3) is highly over-expressed in non-relapsing prostate cancer but not in relapsing prostate cancer. PLoS ONE, 8(1):e54096.

[18]Shukla, G.C., Singh, J., Barik, S., 2011. MicroRNAs: processing, maturation, target recognition and regulatory functions. Mol. Cell. Pharmacol., 3(3):83-92.

[19]Singh, R., Yadav, V., Kumar, S., et al., 2015. MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1. Sci. Rep., 5:17454.

[20]Sugimachi, K., Matsumura, T., Hirata, H., et al., 2015. Identification of a bona fide microRNA biomarker in serum exosomes that predicts hepatocellular carcinoma recurrence after liver transplantation. Br. J. Cancer, 112(3):532-538.

[21]Suzuki, T., Inoue, A., Miki, Y., et al., 2007. Early growth responsive gene 3 in human breast carcinoma: a regulator of estrogen-meditated invasion and a potent prognostic factor. Endocr. Relat. Cancer, 14(2):279-292.

[22]Waller, L.P., Deshpande, V., Pyrsopoulos, N., 2015. Hepatocellular carcinoma: a comprehensive review. World J. Hepatol., 7(26):2648-2663.

[23]Wan, H.Y., Li, Q.Q., Zhang, Y., et al., 2014. MiR-124 represses vasculogenic mimicry and cell motility by targeting amotL1 in cervical cancer cells. Cancer Lett., 355(1):148-158.